English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/124141
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes

AuthorsMartinez-Forero, Ivan; Azpilikueta, Arantza; Bolaños, Elixabet; Nistal-Villan, Estanislao; Palazon, Asis; Teijeira, Alvaro; Pérez-Chacón, Gema ; Morales-Kastresana, Aizea; Murillo, Oihana; Jure-Kunkel, Maria; Zapata, Juan M. ; Melero, Ignacio
Issue Date2013
PublisherAmerican Association of Immunologists
CitationJournal of Immunology 190(12): 6694-6706 (2013)
AbstractAgonist anti-CD137 (4-1BB) mAbs enhance CD8-mediated antitumor immunity. Agonist anti-human CD137 mAbs binding to four distinct epitopes on the CD137 glycoprotein costimulated T cell activation irrespective of the engaged epitope or its interference with CD137L binding. CD137 perturbation with all these agonist mAbs resulted in Ag and Ab internalization toward an endosomal vesicular compartment. Internalization was observed in activated T lymphocytes from humans and mice, not only in culture but also in Ab-injected living animals. These in vivo experiments were carried out upon systemic i.v. injections with anti-CD137 mAbs and showed CD137 internalization in tumor-infiltrating lymphocytes and in activated human T cells transferred to immunodeficient mice. Efficient CD137 internalization required K63 polyubiquitination and endocytosed CD137-containing vesicles recruited TNFR-associated factor (TRAF) 2 and were decorated with K63 polyubiquitins. CD137 stimulation activates NF-κB through a K63-linked polyubiquitination-dependent route, and CD137-associated TRAF2 becomes K63 polyubiquitinated. Consistent with a role for TRAF2 in CD137 signaling, transgenic mice functionally deficient in TRAF2 showed delayed immunotherapeutic activity of anti-CD137 mAbs. As a whole, these findings advance our knowledge of the mechanisms of action of anti-CD137 immunostimulatory mAbs such as those currently undergoing clinical trials in cancer patients.
Publisher version (URL)https://doi.org/10.4049/jimmunol.1203010
URIhttp://hdl.handle.net/10261/124141
Identifiersdoi: 10.4049/jimmunol.1203010
issn: 0022-1767
e-issn: 1550-6606
Appears in Collections:(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
tcellendosom.pdf1,52 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.